We are live on ! Find out more
PTCT icon

PTC Therapeutics

125 hedge funds and large institutions have $636M invested in PTC Therapeutics in 2017 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 41 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.48% more ownership

Funds ownership: 86.37%91.86% (+5.5%)

2% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 41

8% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 26

3% less funds holding

Funds holding: 129125 (-4)

11% less capital invested

Capital invested by funds: $715M → $636M (-$79.6M)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

81% less call options, than puts

Call options by funds: $9.17M | Put options by funds: $48M

Holders
125
Holders Change
-4
Holders Change %
-3.1%
% of All Funds
2.84%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
24
Increased
42
Reduced
41
Closed
26
Calls
$9.17M
Puts
$48M
Net Calls
-$38.9M
Net Calls Change
+$6.04M
Name Holding Trade Value Shares
Change
Change in
Stake
State of Wisconsin Investment Board
76
State of Wisconsin Investment Board
Wisconsin
$400K
AQR Capital Management
77
AQR Capital Management
Connecticut
$389K -$851K -50,289 -68%
State Board of Administration of Florida Retirement System
78
State Board of Administration of Florida Retirement System
Florida
$369K +$2.54K +150 +0.7%
VEA
79
Virtus ETF Advisers
New York
$363K +$36.2K +2,140 +11%
VFA
80
Virtus Fund Advisers
Connecticut
$363K +$368K +21,752 New
California Public Employees Retirement System
81
California Public Employees Retirement System
California
$325K -$260K -15,378 -44%
MIM
82
MetLife Investment Management
New Jersey
$320K +$325K +19,200 New
Wolverine Trading
83
Wolverine Trading
Illinois
$311K +$315K +18,627 New
FDCDDQ
84
Federation des caisses Desjardins du Quebec
Quebec, Canada
$311K
VOYA Investment Management
85
VOYA Investment Management
Georgia
$304K
CEP
86
Chicago Equity Partners
Illinois
$296K
OC
87
Oppenheimer & Co
New York
$292K +$40.6K +2,400 +16%
MCM
88
Matarin Capital Management
New York
$277K -$2.89M -170,486 -91%
VF
89
Virtu Financial
New York
$247K +$251K +14,804 New
Creative Planning
90
Creative Planning
Kansas
$234K +$237K +14,021 New
Teacher Retirement System of Texas
91
Teacher Retirement System of Texas
Texas
$228K +$231K +13,647 New
MA
92
MANA Advisors
New York
$221K +$224K +13,247 New
MLICM
93
Metropolitan Life Insurance Company (MetLife)
New York
$217K -$243K -14,377 -52%
OAM
94
Oxford Asset Management
United Kingdom
$206K -$1.42M -83,686 -87%
Simplex Trading
95
Simplex Trading
Illinois
$205K -$367K -21,700 -64%
Jacobs Levy Equity Management
96
Jacobs Levy Equity Management
New Jersey
$198K +$201K +11,850 New
Nisa Investment Advisors
97
Nisa Investment Advisors
Missouri
$167K
Legal & General Group
98
Legal & General Group
United Kingdom
$166K +$9.12K +539 +6%
Russell Investments Group
99
Russell Investments Group
United Kingdom
$159K
JP Morgan Chase
100
JP Morgan Chase
New York
$144K +$146K +8,651 New

PTCT Hedge Fund Activity: Q4 2017 in Review

125 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2017, worth a combined $636M — down 11% from $715M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of PTCT and 24 opened new positions — a net loss of 2 holders — while 41 trimmed existing stakes and 42 added.

The largest buyer was Scopia Capital Management, adding an estimated $49.9M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $79M sold.

  • 125 institutional investors held PTC Therapeutics (PTCT) as of Q4 2017, down from 129 in Q3 2017.
  • Funds reported $636M of PTC Therapeutics stock for Q4 2017, down 11% quarter-over-quarter.
  • 24 funds opened new PTC Therapeutics positions in Q4 2017 and 26 closed out, a net change of -2 holders.
  • The largest PTC Therapeutics buyer in Q4 2017 was Scopia Capital Management, an estimated $49.9M added.
  • The largest PTC Therapeutics seller in Q4 2017 was Consonance Capital Management, an estimated $79M sold.

Based on aggregated 13F filings for Q4 2017.